A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
Public ClinicalTrials.gov record NCT01245634. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Study Assessing 20 mg/kg Dose of the Recombinant Human Monoclonal Antibody Against P-selectin in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
Study identification
- NCT ID
- NCT01245634
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 384 participants
Conditions and interventions
Interventions
- Placebo Drug
- RO4905417 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2010
- Primary completion
- Apr 30, 2013
- Completion
- Apr 30, 2013
- Last update posted
- Nov 1, 2016
2010 – 2013
United States locations
- U.S. sites
- 27
- U.S. states
- 18
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | 35801 | — |
| Not listed | Tucson | Arizona | 85710 | — |
| Not listed | Los Angeles | California | 90022 | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Atlantis | Florida | 33462 | — |
| Not listed | Jacksonville | Florida | 32216 | — |
| Not listed | Kissimmee | Florida | 34741 | — |
| Not listed | Macon | Georgia | 31201 | — |
| Not listed | Springfield | Illinois | 62702 | — |
| Not listed | Springfield | Illinois | 62769 | — |
| Not listed | Fort Wayne | Indiana | 46804 | — |
| Not listed | Lexington | Kentucky | 405360293 | — |
| Not listed | Dearborn | Michigan | 48123 | — |
| Not listed | Petoskey | Michigan | 49770 | — |
| Not listed | Royal Oak | Michigan | 48073 | — |
| Not listed | Troy | Michigan | 48085 | — |
| Not listed | Duluth | Minnesota | 55805 | — |
| Not listed | Saint Paul | Minnesota | 55102 | — |
| Not listed | Washington | Missouri | 63090 | — |
| Not listed | Stony Brook | New York | 11794 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Toledo | Ohio | 43606 | — |
| Not listed | Memphis | Tennessee | 38120 | — |
| Not listed | Dallas | Texas | 75390-9063 | — |
| Not listed | Salt Lake City | Utah | 84124 | — |
| Not listed | Richmond | Virginia | 23225 | — |
| Not listed | Richmond | Virginia | 23229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01245634, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2016 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01245634 live on ClinicalTrials.gov.